Russian drugmaker eyes expansion in Latin America

Russia’s Research Institute of Highly Pure Biopreparations, a St Petersburg-based producer of active ingredients and drugs, plans to invest up to $20 million in the launch of production of certain drugs against anemia, as well as some active ingredients, with the aim of their further exports, according to the company, reports The Pharma Letter’s local correspondent.

As part of these plans, particular attention will be paid to the organization of supplies to Nicaragua, along with some Latin America and CIS states, says the leading biotechnological institution in Russia.

In the case of active ingredients, at the initial stage the company plans to start the production of an active ingredient of a human recombinant erythropoietin.